(SNY) Sanofi - Ratings and Ratios
Vaccines, Oncology, Immunology, Neurology, Rare Diseases
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.42% |
| Yield on Cost 5y | 5.38% |
| Yield CAGR 5y | 3.83% |
| Payout Consistency | 89.8% |
| Payout Ratio | 51.5% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 24.1% |
| Value at Risk 5%th | 37.2% |
| Relative Tail Risk | -6.00% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.27 |
| Alpha | 0.21 |
| CAGR/Max DD | 0.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.370 |
| Beta | 0.336 |
| Beta Downside | 0.324 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.87% |
| Mean DD | 8.56% |
| Median DD | 8.09% |
Description: SNY Sanofi September 25, 2025
Sanofi (NASDAQ:SNY) is a global biopharma company that discovers, develops, manufactures, and markets therapeutic products across several therapeutic areas, including immunology & inflammation, rare diseases, neurology, oncology, and vaccines. Its vaccine portfolio spans pediatric (polio, pertussis, Hib), respiratory syncytial virus, hexavalent combination vaccines, influenza, meningitis, and travel/endemic vaccines such as hepatitis A, typhoid, yellow fever, and rabies.
The firm maintains an extensive partnership network to augment its pipeline: a collaboration with Exscientia to co-develop up to 15 novel small-molecule candidates for oncology and immunology; agreements with ABL Bio (ABL301 for α-synucleinopathies), Innate Pharma (NK-cell engager targeting B7-H3), Blackstone Life Sciences (clinical development support), IGM Biosciences (IgM antibody platform), Kymera Therapeutics (IRAK4 degraders), Nurix Therapeutics (targeted protein degradation), Denali Therapeutics (systemic inflammatory diseases), Adagene (antibody discovery), Scribe Therapeutics (genome editing), and a co-promotion deal with Provention Bio for teplizumab. Sanofi also partners with Abu Dhabi’s Department of Health on global vaccine initiatives.
Key recent metrics (FY 2023) show revenue of €42.1 billion, with vaccines contributing roughly 15 % and a 9 % YoY increase in oncology sales driven by its Libtayo franchise. R&D expenditure remained steady at €6.5 billion (≈15 % of sales), reflecting continued investment in protein-degrader and gene-editing platforms. Sector-wide drivers that materially affect Sanofi’s outlook include an aging global population (projected to increase demand for chronic-disease therapeutics by ~3 % CAGR through 2030) and heightened vaccine spending post-COVID-19, which is expected to lift the overall vaccine market size to > $70 billion by 2028.
For a deeper quantitative assessment of SNY’s valuation and scenario-based risk/reward profile, the ValueRay platform provides a curated set of peer-adjusted multiples and forward-looking financial models.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (9.11b TTM) > 0 and > 6% of Revenue (6% = 2.53b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 2.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.60% (prev -36.66%; Δ 41.25pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 7.30b <= Net Income 9.11b (YES >=105%, WARN >=100%) |
| Net Debt (12.85b) to EBITDA (9.44b) ratio: 1.36 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.47b) change vs 12m ago -1.52% (target <= -2.0% for YES) |
| Gross Margin 72.56% (prev 69.43%; Δ 3.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 32.89% (prev 37.53%; Δ -4.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.45 (EBITDA TTM 9.44b / Interest Expense TTM 943.5m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 64.31
| 1. Piotroski 5.50pt |
| 2. FCF Yield 6.08% |
| 3. FCF Margin 17.33% |
| 4. Debt/Equity 0.30 |
| 5. Debt/Ebitda 1.36 |
| 6. ROIC - WACC (= 0.77)% |
| 7. RoE 12.36% |
| 8. Rev. Trend 3.51% |
| 9. EPS Trend 10.60% |
What is the price of SNY shares?
Over the past week, the price has changed by +0.97%, over one month by -2.68%, over three months by -0.54% and over the past year by +8.22%.
Is SNY a buy, sell or hold?
- Strong Buy: 5
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 60.6 | 21.2% |
| Analysts Target Price | 60.6 | 21.2% |
| ValueRay Target Price | 54.4 | 8.8% |
SNY Fundamental Data Overview November 20, 2025
P/E Trailing = 16.7195
P/E Forward = 10.3734
P/S = 2.6922
P/B = 1.4462
P/EG = 0.7739
Beta = 0.371
Revenue TTM = 42.14b EUR
EBIT TTM = 7.97b EUR
EBITDA TTM = 9.44b EUR
Long Term Debt = 11.70b EUR (from longTermDebt, last quarter)
Short Term Debt = 8.49b EUR (from shortTermDebt, last quarter)
Debt = 21.75b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.85b EUR (from netDebt column, last quarter)
Enterprise Value = 120.23b EUR (107.38b + Debt 21.75b - CCE 8.91b)
Interest Coverage Ratio = 8.45 (Ebit TTM 7.97b / Interest Expense TTM 943.5m)
FCF Yield = 6.08% (FCF TTM 7.30b / Enterprise Value 120.23b)
FCF Margin = 17.33% (FCF TTM 7.30b / Revenue TTM 42.14b)
Net Margin = 21.62% (Net Income TTM 9.11b / Revenue TTM 42.14b)
Gross Margin = 72.56% ((Revenue TTM 42.14b - Cost of Revenue TTM 11.56b) / Revenue TTM)
Gross Margin QoQ = 74.09% (prev 72.13%)
Tobins Q-Ratio = 0.93 (Enterprise Value 120.23b / Total Assets 129.79b)
Interest Expense / Debt = 1.04% (Interest Expense 227.0m / Debt 21.75b)
Taxrate = 19.38% (680.0m / 3.51b)
NOPAT = 6.43b (EBIT 7.97b * (1 - 19.38%))
Current Ratio = 1.06 (Total Current Assets 34.04b / Total Current Liabilities 32.10b)
Debt / Equity = 0.30 (Debt 21.75b / totalStockholderEquity, last quarter 73.26b)
Debt / EBITDA = 1.36 (Net Debt 12.85b / EBITDA 9.44b)
Debt / FCF = 1.76 (Net Debt 12.85b / FCF TTM 7.30b)
Total Stockholder Equity = 73.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.02% (Net Income 9.11b / Total Assets 129.79b)
RoE = 12.36% (Net Income TTM 9.11b / Total Stockholder Equity 73.71b)
RoCE = 9.33% (EBIT 7.97b / Capital Employed (Equity 73.71b + L.T.Debt 11.70b))
RoIC = 6.94% (NOPAT 6.43b / Invested Capital 92.60b)
WACC = 6.17% (E(107.38b)/V(129.14b) * Re(7.25%) + D(21.75b)/V(129.14b) * Rd(1.04%) * (1-Tc(0.19)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -81.65 | Cagr: -0.79%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈6.05b ; Y1≈7.47b ; Y5≈12.74b
Fair Price DCF = 89.19 (DCF Value 216.63b / Shares Outstanding 2.43b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 10.60 | EPS CAGR: 22.46% | SUE: 0.22 | # QB: 0
Revenue Correlation: 3.51 | Revenue CAGR: 6.46% | SUE: 0.30 | # QB: 0
Additional Sources for SNY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle